pubmed-article:20382274 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20382274 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:20382274 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
pubmed-article:20382274 | lifeskim:mentions | umls-concept:C0003242 | lld:lifeskim |
pubmed-article:20382274 | lifeskim:mentions | umls-concept:C0085732 | lld:lifeskim |
pubmed-article:20382274 | lifeskim:mentions | umls-concept:C1817908 | lld:lifeskim |
pubmed-article:20382274 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:20382274 | pubmed:dateCreated | 2010-5-11 | lld:pubmed |
pubmed-article:20382274 | pubmed:abstractText | Our goal is to compare the immunogenicity and the extent of immunologic reactivity between bispecific and mono anti-idiotype vaccines. We previously obtained two human anti-Id antibody fragments fuse5-G22, fuse5-I50 by phage display technology which were mimics of the antigens from nasopharyngeal carcinoma cell line (HNE2). In this study, we developed and characterized a bispecific anti-Id antibody vaccine G22-I50 and its parent monovalent antibody vaccines G22 and I50. The efficacy of G22-I50, G22, and I50 as tumor vaccines was evaluated in Balb/c mice with three injections of these vaccines adjuvanted with Freund's adjuvant. Mice immunized with G22-I50 exhibited comparable levels of antibody titers and stronger binding inhibition capabilities. Spleen cells from G22-I50-immunized mice gave a significant proliferative response and higher expression level of IFN-gamma and IL-2.These results suggested that bispecific anti-Id antibody vaccine was able to induce more powerful humoral and cell-mediated immune responses, which might make it to be a potential vaccine candidate for the therapy of nasopharyngeal carcinoma. | lld:pubmed |
pubmed-article:20382274 | pubmed:language | eng | lld:pubmed |
pubmed-article:20382274 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20382274 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:20382274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20382274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20382274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20382274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20382274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20382274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20382274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20382274 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20382274 | pubmed:month | Jun | lld:pubmed |
pubmed-article:20382274 | pubmed:issn | 1878-1705 | lld:pubmed |
pubmed-article:20382274 | pubmed:author | pubmed-author:SongJieJ | lld:pubmed |
pubmed-article:20382274 | pubmed:author | pubmed-author:LiuYan-HongYH | lld:pubmed |
pubmed-article:20382274 | pubmed:author | pubmed-author:LiGuan-ChengG... | lld:pubmed |
pubmed-article:20382274 | pubmed:author | pubmed-author:LiYue-HuiYH | lld:pubmed |
pubmed-article:20382274 | pubmed:author | pubmed-author:LiYa-LinYL | lld:pubmed |
pubmed-article:20382274 | pubmed:author | pubmed-author:GuoFeng-JieFJ | lld:pubmed |
pubmed-article:20382274 | pubmed:author | pubmed-author:WangJia-JiaJJ | lld:pubmed |
pubmed-article:20382274 | pubmed:copyrightInfo | Copyright 2010 Elsevier B.V. All rights reserved. | lld:pubmed |
pubmed-article:20382274 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:20382274 | pubmed:volume | 10 | lld:pubmed |
pubmed-article:20382274 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20382274 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20382274 | pubmed:pagination | 707-12 | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:meshHeading | pubmed-meshheading:20382274... | lld:pubmed |
pubmed-article:20382274 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20382274 | pubmed:articleTitle | The ability of human bispecific anti-idiotype antibody to elicit humoral and cellular immune responses in mice. | lld:pubmed |
pubmed-article:20382274 | pubmed:affiliation | Tumor Immunobiology Laboratory of Cancer Research Institution, Central South University, Changsha 410078, Hunan, China. | lld:pubmed |
pubmed-article:20382274 | pubmed:publicationType | Journal Article | lld:pubmed |